STAT
APRIL 18, 2024
As two former secretaries of Health and Human Services, we are all too familiar with the struggle of finding narrow openings for bipartisanship. Despite our different approaches, we believe that addressing health care costs is a truly bipartisan issue. To be serious about creating access for people to the best possible care, that care must be affordable for patients and taxpayers.
BioPharma Dive
APRIL 18, 2024
The start of a so-called rolling review formally begins an FDA evaluation of a closely watched drug that’s important to the biotech’s future, but faces questions about its sales potential.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
APRIL 15, 2024
The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies.
Express Pharma
APRIL 18, 2024
Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes Biocon announced the signing of an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialisation of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
APRIL 16, 2024
A smart sensor developed by Adherium has been cleared by the FDA for use with AstraZeneca's asthma inhaler Airsupra and Breztri for COPD.
STAT
APRIL 18, 2024
An ongoing investigation into data integrity at Dana-Farber Cancer Institute has resulted in a string of retractions, the latest of which is a 2006 Science paper co-authored by institute president and CEO Laurie Glimcher. The retraction notice, published in Science on Thursday, noted that the authors had become aware of discrepancies in key scientific images that led them to lose confidence in key figures in the study, although the study’s lead author opposed the retraction.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
BioPharma Dive
APRIL 18, 2024
Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech.
The Guardian - Pharmaceutical Industry
APRIL 18, 2024
Elizabeth Hanna says she was fired by the American Diabetes Association after refusing to approve recipes heaped with the additive made by a major donor Elizabeth Hanna had a simple job: help people with diabetes figure out what to eat. Anyone with common sense knows this should probably not entail foods that might increase people’s risk of getting diabetes.
pharmaphorum
APRIL 18, 2024
UK researchers describe an algorithm that is more accurate than current tools at predicting an individual’s risk of developing cardiovascular disease in the next 10 years.
STAT
APRIL 18, 2024
For a company moving as quickly as possible to build artificial intelligence into everything — including health care — Microsoft spends a lot of time talking about how to regulate it. The tech giant has helped organize four separate coalitions to devise guidelines and technical standards for AI in health care. It supplies these groups — composed of health systems, government regulators, and other health businesses — with top executives to serve on steering committees,
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
ID Stewardship
APRIL 14, 2024
In this article a comparison of Rebyota versus Vowst is provided, to help learners differentiate these two fecal microbiota therapies. Authored by: Natalie Boyer, Pharm.D. Candidate 2025 Mentored by: Christina G. O’Connor, Pharm.D., PharmD, BCPS, BCIDP, AAHIV-M Disclaimer : This text and table is intended for use as a study tool to assist people learning pharmacotherapy of recurrent Clostridioides difficile infections (rCDI).
BioPharma Dive
APRIL 15, 2024
Treatment appeared to result in functional and cognitive gains in people with the neurological disorder. Three participants experienced lower extremity weakness, however.
PharmaTech
APRIL 12, 2024
The agency’s risk assessment committee has concluded that available evidence has not been found that supports a causal association between glucagon-like peptide-1 receptor agonists and self-harming thoughts and actions.
pharmaphorum
APRIL 16, 2024
Researchers from the UK have developed an endoscopic device that uses 3D imaging to look at the stiffness of cells and could diagnose cancer earlier.
STAT
APRIL 17, 2024
Eli Lilly reported positive results for its obesity drug Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market. The results also pave the way for Zepbound to potentially become the first approved treatment for obstructive sleep apnea, or OSA, a common disorder characterized by breathing interruptions during sleep.
Pharma Times
APRIL 15, 2024
Affecting over 500,000 people in the UK, IBD comprises Crohn’s disease and ulcerative colitis
Pharmaceutical Technology
APRIL 16, 2024
The price ceiling policy has been in place for more than 20 years, but it has neither been very successful nor free of consequences for pharma companies.
Outsourcing Pharma
APRIL 18, 2024
Yesterday, Thermo Fisher Scientific opened its first Innovation Lab in Center Valley, Pennsylvania., as a space where partners can come together to collaborate, innovate, and ideate on solutions to the biggest clinical supply chain pain points.
pharmaphorum
APRIL 18, 2024
Embark on an omnichannel marketing odyssey by exploring the top trends reshaping the industry in 2024. Discover how chatbots, video content, and interactivity are transforming marketing strategies.
STAT
APRIL 18, 2024
In the chaotic first few months of the Covid-19 pandemic, stores faced shortages of all kinds — toilet paper, canned food, and especially, cleaning supplies. With everyone scrubbing their groceries, mail, even library books, good luck finding antibacterial wipes or disinfectant sprays back then. That’s because public health advice in early 2020 focused on sanitizing surfaces, not protecting against a virus that could be spread through the air.
The Pharmacist
APRIL 12, 2024
The number of phone calls to pharmacies more than tripled between February and March 2020, while home deliveries of medication to vulnerable patients more than doubled, the UK Covid-19 Inquiry heard this week. Speaking on behalf of the National Pharmacy Association (NPA) at the inquiry hearing this week, legal representative Deirdre Domingo, said members had […] The post Calls to pharmacies tripled during pandemic, inquiry told appeared first on The Pharmacist.
Orsini Pharmacy
APRIL 18, 2024
ELK GROVE VILLAGE, Ill. , April 18, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy has been selected by Edenbridge Pharmaceuticals as the preferred specialty pharmacy partner for the distribution of Yargesa (miglustat) capsules, 100mg. YARGESA is a glucosylceramide synthase inhibitor indicated for the treatment of adult patients with Type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.
BioPharma Dive
APRIL 15, 2024
Because live cell and tissue products are extremely sensitive to contamination from microorganisms, viral particles or other airborne impurities, research and manufacturing involving these materials needs to be conducted in a cleanroom environment.
pharmaphorum
APRIL 17, 2024
Sage Therapeutics has suffered another disappointment after deciding that it will have to drop the Parkinson’s programme for key pipeline drug dalzanemdor after it showed no benefit in a phase 2 trial. The oral positive allosteric modulator (PAM) of the NMDA receptor is being investigated to see if it can counteract mild cognitive impairment in neurodegenerative disorders, and the PRECEDENT trial in Parkinson’s is the first major readout from the drug programme.
STAT
APRIL 17, 2024
A new analysis of health inequities in the United States shows that every state has deep racial and ethnic disparities in the performance of their health care systems. The report released Thursday by the Commonwealth Fund analyzed 25 indicators that track health outcomes, health care access, and quality of care provided for five racial and ethnic groups.
Pharma Times
APRIL 12, 2024
NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases
Drug Patent Watch
APRIL 16, 2024
The pharmaceutical industry in China is undergoing a significant transformation with the adoption of artificial intelligence (AI) technology.
BioPharma Dive
APRIL 15, 2024
Learn about why access to robust biomarkers such as cfHPV-DNA is pivotal in determining eligibility, assessing treatment response and detecting recurrence early to improve patient outcomes.
pharmaphorum
APRIL 17, 2024
The FTC is seeking a $7 million fine on telehealth company Cerebral for violating patients' data privacy and making cancellation difficult.
STAT
APRIL 17, 2024
When my son Conall took his life at age 17, it was devastating to me and our entire family. Conall was a caring, empathetic, and bright young man, but he had also struggled for many years with anxiety and depression. Like many kids his age, much of his life revolved around social media. While I understand that suicide is complex, with many different factors contributing to someone’s risk for it, I know that social media intensified and fueled Conall’s insecurities and ultimately ha
Express Pharma
APRIL 16, 2024
Panelists in this video: + Mr SG Belapure, Sr. Technical Advisor, IPA (Moderator) + Dr Viranchi Shah, National President, Indian Drug Manufacturers Association (IDMA) + Mr Vijay Charlu, President, Corona Remedies + Mr Rajiv Gandhi, CEO & MD, Hester Biosciences + Mr Sanjay Sharma, Sr VP & Head-Manufacturing Science and Technology, Zydus Group Key Highlights: [1] An entrepreneurial mindset, conducive business climate and presence of good resources have made Ahmedabad a leading pharma hub
Outsourcing Pharma
APRIL 17, 2024
Pharma companies need to take greater ownership to make sure data quality and governance is accomplished - and it is important to keep in mind the ethics of AI use will remain front and centre for the pharma industry.
PioneerRx
APRIL 16, 2024
It’s the most wonderful time of year for PioneerRx. Catalyst Connect 2024 is rapidly approaching, where pharmacists and other healthcare professionals.
pharmaphorum
APRIL 15, 2024
Shah Capital has fired a broadside at the management team of Novavax, seeking a change in leadership at the vaccine company and the appointment of two handpicked directors to the board. In an open letter, the hedge fund accuses Novavax’s leadership of squandering its “many significant competitive advantages and sizeable market opportunity” due to “self-inflicted problems” under the current team led by chief executive John Jacobs.
STAT
APRIL 14, 2024
As diligent taxpayers breathe a sigh of relief that the hassle of filing their tax forms is over for another year, the Internal Revenue Service continues to let most U.S. hospitals pay nothing in federal taxes. It’s time for Congress to take a hard look at the IRS’s hand in health care. The agency uses a vague “community benefit” standard to liberally grant tax-exempt status to so-called nonprofit hospitals even as many of them are financially taking advantage of sick
Expert insights. Personalized for you.
344 
Let's personalize your content